Jeevan Scientific Technology Ltd

Jeevan Scientific Technology, a microcap in the Pharmaceuticals & Drugs sector, hit a new 52-week low today after significant volatility. The stock has underperformed the sector and is trading below all major moving averages, reflecting a sustained downward trend amid broader industry challenges.

Jeevan Scientific Technology, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today after two days of gains. The stock exhibited high volatility, with significant intraday fluctuations and a notable decline over the past year, underperforming compared to broader market indices.

Jeevan Scientific Technology has announced its financial results for the quarter ending December 2024, reporting a profit after tax of Rs 0.35 crore, a turnaround from a loss in the previous year. Net sales reached Rs 12.51 crore, indicating a year-on-year growth of 23.49%.

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has reported positive financial performance in the second quarter of fiscal year 2024-2025, with a 41.44% increase in net sales and higher profit after tax. However, the company's stock has received a 'Sell' call and its dividend payout ratio is at its lowest in five years. Investors should carefully evaluate all factors before investing.

Jeevan Scientific Technology, a microcap company in the pharmaceutical industry, has announced its financial results for the quarter ending March 2024. Despite receiving a 'Sell' call from MarketsMOJO, the company has shown positive performance with significant improvements in key financial metrics such as PBT, PAT, net sales, and operating profit.

Jeevan Scientific Technology, a microcap pharmaceutical company, reported its highest net sales in the last five quarters at Rs 11.07 crore for the quarter ending March 2024. The company also showed a 39.60% growth in net sales compared to the same quarter last year. Despite a 'Strong Sell' call by MarketsMOJO, the company's overall score has improved, indicating efforts to improve its financial performance.

Jeevan Scientific Technology, a microcap pharmaceutical company, has reported a flat performance for the quarter ending December 2023. This comes after the company's stock was given a 'Sell' call by MarketsMOJO. However, the company remains focused on its operations and is committed to delivering quality products to its customers. Investors are advised to do their own research before making any investment decisions.

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has been downgraded to a 'Sell' by MarketsMOJO due to poor long-term growth and flat results in September 2023. The stock is also considered risky and has underperformed the market in the last year. While the company has a strong ability to service debt, its overall outlook is not favorable.

Jeevan Scientific Technology, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its strong debt servicing ability and positive technical indicators. However, the company has shown poor long-term growth and underperformed in the market, making it a potentially risky investment.

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has received a 'Sell' rating from MarketsMOJO due to its poor long-term growth and flat financial results. The stock is considered risky with negative operating profits and below-average valuations. However, it has a strong ability to service debt and technical factors show a Bullish trend. Majority of shareholders are non-institutional investors, potentially leading to higher volatility.

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to EBITDA ratio of 0.86 times. However, the company has shown poor long-term growth and underperformed the market, making it a risky investment. Investors should carefully consider these factors before making any decisions.

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has reported a decline in net sales, net profit, and operating profit for the quarter ended September 2023. The company's stock has been given a 'Sell' rating by MarketsMOJO due to its poor financial performance. This news is relevant for investors in the pharmaceutical industry.

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has received a 'Sell' rating from MarketsMOJO due to its poor long-term growth and flat recent results. The stock is considered risky with negative operating profits and a lack of growth potential. However, the company has a strong ability to service debt and a majority of non-institutional shareholders. Investors should carefully consider these factors before investing.